Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

News Cuanschutz

Published November 17, 2026 · Updated November 18, 2026

Psilocybin May Improve a Difficult-to-Treat Symptom of Depression, CU Anschutz Study Finds

Read the full story at News Cuanschutz

A small clinical trial from the University of Colorado Anschutz suggests that psilocybin , a psychedelic compound found in certain mushrooms , may.

Surfaced by this Google Alert

  • Magic mushrooms